Elritercept (KER-050)

A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)

Near Add Your Location

Sorting 3 by

Center of Excellence

City of Hope Comprehensive Cancer Center
Beckman Research Institute
Duarte, CA
  • Accepting patients

Center of Excellence

Sylvester Comprehensive Cancer Center (Main)
University of Miami Health System
Miami, FL
  • Accepting patients

Center of Excellence

Moffitt Cancer Center
Magnolia Campus
Tampa, FL
  • Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.